Scholarlink

Introduction <p>Tinidazole shows potential as a first-line treatment for bacterial vaginosis (BV). However, its superiority to metronidazole remains uncertain. Therefore, this meta-analysis compares tinidazole versus metronidazole in patients with BV.</p> Methods <p>We systematically searched PubMed, Embase and Cochrane for studies comparing tinidazole and metronidazole in patients with BV. Statistical analyses were performed using R Studio 4.3.2. Heterogeneity was examined with the Cochran Q test and I<sup>2</sup> statistics. Risk ratios (RR) with 95% confidence intervals (CI) were pooled across trials. Outcomes of interest were BV cure at the first and the second follow-up appointment, and adverse events such as nausea and bad or metallic taste.</p> Results <p>Five randomized controlled trials and 1 prospective observational study, reporting data on 1,036 patients were included in this meta-analysis. Among them, 511 (49%) received tinidazole and 525 (51%) received metronidazole. Follow-up ranged from 1 to 6&#xa0;weeks. There was no significant difference between groups for BV cure at the first follow-up appointment (RR 1.03; 95% CI 0.92 to 1.14; I<sup>2</sup> = 76%), cure at the second follow-up appointment (RR 1.05; 95% CI 0.80–1.38; I<sup>2</sup> = 88%), nausea (RR 0.89; 95% CI 0.39–2.04; I<sup>2</sup> = 83%), and bad or metallic taste (RR 0.74; 95% CI 0.12–4.45; I<sup>2</sup> = 89%).</p> Conclusion <p>In patients with BV, tinidazole and metronidazole exhibit similar efficacy and safety, with equivalent cure rates and incidence of adverse events.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tinidazole vs metronidazole for the treatment of bacterial vaginosis: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月19日

查看全文
  • Milene Vitória Sampaio Sobral,
  • Victor Gonçalves Soares,
  • João Lucas de Magalhães Leal Moreira,
  • Livia Kneipp Rodrigues,
  • Hilária Saugo Faria,
  • Clara de Andrade Pontual Peres,
  • Lubna Al-Sharif,
  • Maria Julia Gonzaga Pascoalin,
  • Fernando Augusto Barreiros,
  • Marina Ayabe Gomes de Moraes

摘要

Introduction

Tinidazole shows potential as a first-line treatment for bacterial vaginosis (BV). However, its superiority to metronidazole remains uncertain. Therefore, this meta-analysis compares tinidazole versus metronidazole in patients with BV.

Methods

We systematically searched PubMed, Embase and Cochrane for studies comparing tinidazole and metronidazole in patients with BV. Statistical analyses were performed using R Studio 4.3.2. Heterogeneity was examined with the Cochran Q test and I2 statistics. Risk ratios (RR) with 95% confidence intervals (CI) were pooled across trials. Outcomes of interest were BV cure at the first and the second follow-up appointment, and adverse events such as nausea and bad or metallic taste.

Results

Five randomized controlled trials and 1 prospective observational study, reporting data on 1,036 patients were included in this meta-analysis. Among them, 511 (49%) received tinidazole and 525 (51%) received metronidazole. Follow-up ranged from 1 to 6 weeks. There was no significant difference between groups for BV cure at the first follow-up appointment (RR 1.03; 95% CI 0.92 to 1.14; I2 = 76%), cure at the second follow-up appointment (RR 1.05; 95% CI 0.80–1.38; I2 = 88%), nausea (RR 0.89; 95% CI 0.39–2.04; I2 = 83%), and bad or metallic taste (RR 0.74; 95% CI 0.12–4.45; I2 = 89%).

Conclusion

In patients with BV, tinidazole and metronidazole exhibit similar efficacy and safety, with equivalent cure rates and incidence of adverse events.